Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Kinross Gold Corporation — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while Kinross Gold Corporation trades at $22.71 (market cap $26.40B). The key difference: Kinross Gold Corporation is far larger — about 9.4× Dyne Therapeutics Inc. Common Stock's market cap, and Kinross Gold Corporation pays a 0.72% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Kinross Gold Corporation for 53 Days on average.
| DYN | KGC | |
|---|---|---|
Market Cap | $2.81B | $26.40B |
Volume | 2,195,902 | 10,366,257 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $38.06 |
52-Week Low | $14.60 | $22.24 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $2.13B | $24.48B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Kinross Gold (KGC) trades at $23.44, down 0.47% on the day, amid a bearish technical signal despite strong fundamental performance. The company reported robust earnings beats in recent quarters with Q2 2026 EPS of $0.71 exceeding expectations, while revenue grew to $7.05 billion in 2025. However, recent news highlights production guidance cuts for 2026-2027 and ongoing legal investigations, creating mixed sentiment. Technical indicators show the stock trading near key support at $23 with RSI levels suggesting potential oversold conditions.
KGC presents a compelling value opportunity with attractive valuation multiples (P/E 8.91, EV/EBITDA 4.6) and strong profitability margins (net income margin 37.52%). The company's increasing cash flow generation and shareholder return framework support upside potential toward the $38.80 consensus price target. Key risks include production challenges at key mines, rising operating costs, and legal uncertainties that could pressure near-term performance despite the positive long-term gold price environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
